Considering that oncogenic activation of the EGFR pathway results in an immune-inert phenotype and recent literature has implicated a potential role of YY1 in mediating tumor immune escape [36, 43–46], these conclusions may also be tentatively extrapolated to cancer immunotherapy. This evidence concerns the gene EGFR and cancer.